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The role of modelliNg aNd SimulaTioN  
iN CliNiCal pharmaCology
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Summary: Pharmacokinetics is a field that has matured over the 
last 40 years, and we now have a detailed pharmacologic and physi-
ological understanding of “what the body does to a drug.” The sub-
ject has reached a point whereby reasonably accurate prediction of 
human pharmacokinetic behavior of a chemical, based on its physico-
chemical properties and some in vitro experimentation, is possible. 
Pharmacodynamics as a discipline is even older than pharmacokinet-
ics, but we are not in such a strong position in terms of prediction 
of human pharmacodynamics, as we are with pharmacokinetics. 
However, pharmacokinetic/pharmacodynamic (PKPD) modeling is 
making rapid strides. PKPD is very much a quantitative discipline 
in the sense that theory can be translated into temporal profiles of 
concentration or response, even to the extent of being able to design 
dosage regimens for individual patients. The hub of this quantita-
tive discipline is a PKPD model, and PKPD modeling has become an 
essential activity in preclinical and clinical drug development and 
clinical drug usage.
Recently, the European Medicines Agency (EMA) and the 
European Association of Pharmaceutical Industries and Associates 
(EFPIA) brought together key opinion leaders and regulatory and 
academia experts from Europe and beyond to discuss the role of 
modeling and simulation (M&S) in areas such as early medicine 
development, clinical pharmacology and dose-finding studies, special 
populations, optimization, and analysis of pivotal clinical trials.1 The 
fact that this meeting occurred indicates there is a meeting of minds 
on the role of modeling in drug development in particular, across a 
range of stakeholders. Perhaps modeling is coming in from the cold 
and is now being seen as part of the solution rather than as part of 
the problem.
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NoN iNfeCTiouS iNTermediaTe  
aNd poSTerior uVeiTiS: TreaTmeNT  
aNd plaCe of loCal STeroidS
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Summary: Corticosteroids are considered to be the mainstay of ther-
apy in noninfectious uveitis, until now, but side effects and complica-
tions related to such therapy, if systemically given, are well known. 
This is why in the recent period many local therapies have been 
proposed to treat noninfectious uveitis, especially intermediate and 
posterior. Corticosteroids can be given periocularly and intravitreally. 
Sub-Tenon injection (either via the orbital floor or transconjunctivally 
in the supero-temporal quadrant) with long-lasting steroids can be 
used every 15 to 60 days, and it is able to control uveitis as well 
as to treat macular edema. Apart from typical ocular side effects 
related to steroid therapy, such as cataract and intraocular pressure 
(IOP) increase, this way of administration can induce conjunctival 
and orbital floor fibrotic reaction, ptosis, retrobulbar hemorrhages, 
muscles paresis, optic nerve injury, and globe perforation. Intravitreal 
administration of steroids can be done either with a direct injection 
of triamcinolone, or with the placement into the vitreous cavity of a 
biodegradable dexamethasone implant (700 μ g, 4–6 months’ dura-
tion) or of a device able to deliver continuously for almost 3 years 
fluocinolone acetonide (0.59 mg). Their efficacy has been widely 
proven in treating noninfectious uveitis, but some local side effects 
(dexamethasone biodegradable implant: IOP increase in 25% of the 
patients; fluocinolone implant: cataract in 93% of the cases, IOP 
increase in 77%, 37% of whom requiring a surgical approach) 
could limit their use. In neither of the 2 aforementioned approaches 
is there a significant risk of developing endophthalmitis or retinal 
detachment. A questionable use of local therapy is in patients with 
an associated systemic disease and/or in those with bilateral uveitis. 
Nevertheless, in such a case, it is not rare to observe a very severe 
inflammatory ocular involvement with few systemic symptoms, 
and/or an asymmetric presentation of uveitis, which can be usefully 
comanaged with local, either periocular or intravitreal therapy.
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Summary: Abundant evidence from reviews of published research 
articles has demonstrated that a substantial proportion lack key 
information. A fundamental principle is that readers need to know 
exactly what was done and be given an accurate, complete and trans-
parent account of what was found. Readers should not be expected 
to take on trust that the authors have done a study without flaws. 
Furthermore, in principle, there should be enough detail to allow 
replication.
Widespread deficiencies in research publications weaken the 
evidence base for clinical practice. How can it be that none of the 
authors, peer reviews, or editors has detected that so many articles 
are substandard and, indeed, often unfit for purpose? Ensuring that 
journal articles are of maximum value to readers should be a priority 
for those who write research articles and those who review them. In 
recent years, many reporting guidelines have been developed, outlin-
ing the key elements of research that should be reported, with as-yet 
modest success. These and other related resources are available on 
the Web site of the EQUATOR Ne2rk. The best-known reporting 
guideline is the CONSORT Statement for reporting randomized tri-
als. Several extensions of CONSORT have been published. In this 
context, I will discuss the reporting of early clinical studies in phar-
macology.
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Summary: Major depression is a severe psychiatric syndrome with 
very high prevalence and socioeconomic impact. Its pathophysiology 
is poorly known, yet several neurotransmitter systems and brain areas 
have been implicated. Selective serotonin (5-hydroxytryptamine [5 
(-HT)]) reuptake inhibitors (SSRIs) and serotonin and norepinephrine 
reuptake inhibitors (SNRIs) are the most used antidepressant treat-
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ments. However, these drugs show slow onset of action and limited 
efficacy, making necessary the use of drug augmentation strategies 
or more aggressive interventions. Two important observations have 
emerged in recent years indicating that more rapid and effective 
antidepressant treatments are possible. On the one hand, the deep 
brain stimulation (DBS) of ventral anterior (subgenual) cingulate 
cortex (Cg25) evokes rapid mood improvements in subgroups of 
treatment-resistant depressive patients, likely mediated by a func-
tional remodeling of cortico-limbic circuits. On the other hand, the 
noncompetitive NDMA receptor antagonist ketamine can also evoke 
raid (eg, 2 hours) and persistent (up to 1 week) improvements in some 
treatment-resistant patients. Moreover, recent preclinical observa-
tions indicate the antidepressant capacity of nGluR agents. Overall, 
this supports the usefulness of glutamatergic transmission as a new 
area in antidepressant drug development. On the monoamine side, 
new preclinical and clinical research should clarify the different roles 
played by 5-HT receptors in depression as well as the brain areas and 
circuits responsible for therapeutic improvement. This will lead to the 
synthesis of new agents blocking the serotonin (and possibly norepi-
nephrine) transporter, which will also activate or block 5-HT recep-
tors playing, respectively, positive (eg, postsynaptic 5-HT1A, 5-HT4) 
or negative (eg, presynaptic 5-HT1A,/1B, 5-HT2A, 5-HT2C,5-HT3) 
roles in antidepressant effects.
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Summary: Intravenous fat emulsion (IFE) has been used as an 
antidote and is most extensively studied for the treatment of local 
anesthetic toxicity. New applications beyond local anesthetic are pro-
posed, including calcium channel blockers, cyclic antidepressants, 
clomipramine, and β -adrenergic antagonists. There are 3 proposed 
mechanisms of action of IFE in toxicology: modulation of intra-
cellular metabolism, a lipid sink or sponge mechanism, and activa-
tion of ion channels. The lipid sink/sponge model is the most likely 
mechanism. Several experimental models demonstrate the benefit of 
IFE in bupivacaine, calcium channel blockers, cyclic antidepressants, 
and β -adrenergic antagonist toxicity. Multiple case reports using IFE 
in a variety of drug toxicity report improvement. Potential adverse 
effects may limit use but have been reported infrequently, and the 
benefit of IFE may outweigh potential risks. The dose, timing of 
administration, and the uses and comparison with other treatments 
are in need of future studies. The recommended dose of 20% IFE is a 
1.5-mL/kg bolus followed by 0.25 mL/kg/min or 15 mL/kg/h to run 
for 30 to 60 minutes. The bolus can be repeated several times for 
persistent asystole, and the infusion rate can be increased if blood 
pressure decreases.
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Summary: Paracetamol poisoning was first reported > 45 years ago, 
but its optimum management is still a matter of debate. In part this 
is because of the difficulty in precise risk stratification early in poi-
soning and a lack of effective antidotal treatments for those who 
present late after ingestion. National drug regulatory and poisons 
information systems in different countries provide different advice, 
and the United Kingdom changed its risk stratification advice in 2012 
after > 30 years. Observational data suggest that repeated ingestions 
of lower doses may cause more severe liver damage than a single 
ingestion, but the reasons for this remain unclear. The antidote IV 
acetylcysteine is given in a complex dose regimen that is not tailored 
to the amount of toxin ingested, and the initial duration of antidote 
therapy was determined empirically in the mid-1970s. Adverse effects 
to the antidote acetylcysteine are a further challenge, as they are more 
frequent at lower paracetamol concentrations.
We have recently been able to establish a population estimate of 
risk, which shows that early presentation managed conventionally 
results in good outcome and that mortality is almost always in those 
presenting > 15 hours after first ingestion. Co-ingestion of other drugs 
that delay gastric motility and the introduction of modified-release 
paracetamol products further complicate management approaches, 
and the safety of marketing of SR preparations must be questioned 
from a public health perspective. New biomarkers offer the potential 
to better identify patients who are at specific risk, and appear to pre-
cede, and better predict, than rises in the traditional transaminases. 
Newer, modified acetylcysteine regimens should improve its safety 
profile. Linked to new biomarkers, these potentially offer shorter 
durations of hospital stay for paracetamol overdose.
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Summary: Progress in the treatment of inborn errors of metabolism 
has derived from insight into their causes and has focused on nutri-
tional limitation of a substrate or replacement of missing products, 
the removal of toxic metabolites and maximizing anabolism, or com-
pensatory expression of a protein whose deficiency causes disease 
through stem cell or organ transplantation.
The knowledge of the biochemistry and the pathway of lysosomal 
enzymes and the concept of systemic delivery of a deficient enzyme 
carrying a mannose-6-phosphate residue that serves as recognition 
marker for both uptake and transport to lysosomes resulted in the 
first successful enzyme replacement therapies in patients with lyso-
somal storage disorders.
The use of small molecules as therapeutic agents is another 
approach that is being applied widely to inborn errors of metabolism. 
This is illustrated by substrate reduction therapy, which has shown 
to be effective in some lysosomal storage disorders and complements 
some of the limitations of enzyme-replacement therapy (eg, crossing 
the blood-brain barrier). Pharmacologic chaperones generally bind 
directly to mutant proteins and mediate improvement in the folding, 
the transport, or the stability and hence elevated levels of mutant 
protein with residual function. One example for this is treatment 
with pharmacologic doses of cofactor or cofactor analogues such as 
in phenylketonuria. Other novel therapeutic approaches include the 
use of “old” approved drugs to compensate for functional deficits or 
antagonize unwanted effects. One example is the use of losartan to 
reduce TGF-b activity in Marfan’s syndrome and other genetically 
caused forms of aortic aneurysm.
Finally, new developments will be discussed such as manipulation 
of gene expression by suppression of nonsense-mediated decay or 
manipulation of pre-mRNA splicing using short oligonucleotides. 
